GKOS · GLAUKOS Corp
$164.19
+5.64 (+3.56%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$9.11B
Shares
58.98M
Volume · Sep 30
947.09K
Avg daily vol (3M)
796.93K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$164.19
Open$158.31
Day$157.29–165.65
52W close$74.67–189.55
Avg vol 30d755K
Short int4.2M · 7.1% float · 5.7d
Short vol75%
Last earningsJul 29, 2026
DataJan 2020–Sep 2026
Filing10-Q · Jul 29
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 4 wks
filed Jul 29, 2026
call held Jul 29, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$612.84M
Trailing 12 months
Net income (TTM)
−$188.05M
Trailing 12 months
Revenue growth YoY
+49.5%
Year over year
Operating margin
-31.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.8%
Year over year · more shares
Price change (1Y)
+95.1%
Trailing year
Short interest
7.1%
Latest settlement · 5.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
−4%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
78%
mid-range
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+37%
trailing
YTD return
+45%
this year
Relative strength
+25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $172 › 200d $135 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +69 funds added
Insider flow
Distributing
Net -$13.8M over 90 days · 100% sells
Short interest
Rising
7.06% of float · ▲ +9.0% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
367 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+32%
Y/Y
Gross margin
56%
contracting
EPS growth
−18%
Y/Y
Free cash flow
$-22.5M
Balance sheet
$11.9M
net cash
Quant / Vol
risk profile
Volatility
52%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 29, 2026
Net sales
· 2026
$680M – $700M
prior FY $507.44M
midpoint +36.0% Y/Y
Guided vs delivered
· last 2 settled
Net sales
2021
guided $285M – $290M
$294.01M
Beat +2.3%
Net sales
third quarter 2021
guided $72M – $74M
$74.71M
Beat +2.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
−4%
Neutral
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
78%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $172 › 200d $135 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +69 funds added
Insider flow
Distributing
Net -$13.8M over 90 days · 100% sells
Short interest
Rising
7.06% of float · ▲ +9.0% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
367 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $75
Now $164 · 78%
Range high $190
vs 200-day avg +22%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GKOS
this stock
GLAUKOS Corp
|
$9.11B | +45.4% | +32.3% | — | 7.1% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GKOS | +7.0% | -7.1% | +37.5% | -8.6% | +45.4% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +7.6% | -7.2% | +25.3% | -8.0% | +33.6% |
Key facts
CIK
1192448
CUSIP
377322102
13F (30d)
11 filings
10 filers
Visit website
Investor relations